BVS (Bioventus) Dividends Received


BVS Bioventus Inc BVS
60 GF Score
Price $11.88
GF Value $6.81
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bioventus Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

BVS
60GF Score
Bioventus Inc BVS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioventus (BVS) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventus stock appears to be overvalued. The current stock price of $11.88 is trading 74.4% above its estimated GF Value™ of $6.81. GuruFocus considers Bioventus to be Significantly Overvalued.

Key valuation signals for BVS:

  • Dividends Received:
  • GF Value™: $6.81 vs. price of $11.88 (74.4% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the BVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioventus Business Description

Other Exchanges 4B8:Germany
Address 4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
60GF Score

Get the complete analysis for BVS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.88
Price
$6.81
GF Value